RBC Capital upgraded IGM Biosciences Inc (NASDAQ:IGMS), a biotechnology focused on antibody medicines for cancer.
RBC analysts upgraded the stock to Outperform from Sector Perform rating with a price target of $21, up $9.
The mechanistic understanding behind B-cell depletion leading to remission of autoimmune diseases has generated significant interest. In recent years, RBC Capital writes that IGM Biosciences has adeptly positioned itself as a potential contributor in this field.
There is evidence for the curative potential of CAR-T in lupus, and a thorough examination of preclinical and clinical data for imvotamab and similar agents indicates that IGM …
Full story available on Benzinga.com